Determination of Pharmaceuticals from Serum
The Application Notebook
This application note describes the determination of pharmaceuticals from serum using solid-phase extraction with the hydrophilic-lipophilic balanced SPE phase CHROMABOND® HLB for analyte enrichment and for sample clean-up. The eluates from SPE are finally analyzed by HPLC–MS/MS on a NUCLEOSHELL® PFP core-shell phase.
Nowadays, people are suffering from various diseases. Therefore, they are prescribed many types of pharmaceuticals as part of their treatment, for instance anesthetics, antibiotics, anticholinergics, anticonvulsants, etc. In order for the treatment to be successful, it is necessary to keep controlling the levels of the pharmaceuticals to provide an accurate dosage. This leads to an increasing demand for the development of accurate and sensitive analytical methods for the pharmaceuticals from serum to protect human health.
Table I: SRM transitions for the investigated pharmaceuticals.
Solid-Phase Extraction (1)
Click here to view full-size graphic
Subsequent Analysis: HPLC–MS/MS (2)
Click here to view full-size graphic
Results
The recovery rates show that the determination of pharmaceuticals from serum could be carried out successfully (Figure 2). By using SPE with CHROMABOND HLB it was possible to recover nearly all pharmaceuticals from serum on average with good reproducibility. Regarding the different types pharmaceuticals of the average recovery rates were: for anesthetics 90.8%, for antibiotics 94.4%, for anticholinergics 84.8%, for anticonvulsants 97.7%, for antidepressants 77.4%, for antihistamines 87.1%, for anti-inflammatory drugs 84.1%, for beta blockers 89.5%, for calcium channel blockers 107.5%, and for diuretics 87.7%
Figure 2: Recovery rates for solid-phase extraction method of pharmaceuticals from serum.
The identification and quantification of pharmaceuticals in the solid-phase extracts were carried out by ESI mass spectrometry on an EC 50/2 NUCLEOSHELL PFP column. The chromatogram in Figure 1 shows the results of solid-phase eluate spiked with 10 ng/mL serum for each pharmaceutical.
Figure 1: Chromatogram of serum sample spiked with 10 ng/mL for each pharmaceutical.
Conclusion
The presented application describes a quick and convenient method for the determination of pharmaceuticals from serum by SPE with a hydrophilic-lipophilic balanced phase, followed by HPLC–MS/MS analysis.
References
(1) Application No. 306510, MACHEREY-NAGEL, available from www.mn-net.com/apps
(2) Application No. 128200, MACHEREY-NAGEL, available from www.mn-net.com/apps
Macherey-Nagel GmbH & Co. KG
Neumann-Neander-Str. 6–8, 52355 Düren, Germany
tel. +49-(0)2421-969-0
Website: www.mn-net.com
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
